You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1952 Results
Regimen
Cancer Type:
Head and Neck, 
Salivary Gland
Intent: Palliative
Jul 2022
Regimen
Intent: Palliative, Adjuvant
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Adjuvant
Nov 2017
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Jun 2019
Regimen
Intent: Palliative
Apr 2023
Regimen
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Apr 2023
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Apr 2023
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
May 2025

Pages